試す 金 - 無料
Can rate cuts help budget housing?
Mint Chennai
|December 08, 2025
Limited space
The Reserve Bank of India (RBI) trimmed the repo rate by 25 basis points (bps) on Friday, taking the key lending rate to 5.25%. With this, the total repo rate reduction in 2025 is 125 bps. As banks begin to adjust lending rates, equated monthly instalments (EMIs) would tread lower and home loans could get cheaper. Typically, it should benefit the beleaguered affordable housing segment as it is more sensitive to interest rate movements.
“(Our) sensitivity analysis indicates that every 1% cut in the base lending rate results in a 0.24% increase in priority-sector home loans,” said Vivek Rathi, national director - research, Knight Frank India. Borrowers in the priority sector are typically from the economically weaker sections and lower income groups, also eligible for schemes like the Pradhan Mantri Awas Yojana (PMAY) subsidy.
このストーリーは、Mint Chennai の December 08, 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Mint Chennai からのその他のストーリー
Mint Chennai
Barrier-free tolling runs into a Chinese camera security bump
Commuters looking to zoom past toll plazas on India's 146,560 km highway network will have to wait longer.
1 min
February 26, 2026
Mint Chennai
A new grammar to challenge Tamil film
Members of the Problematic Family, which premiered at the Berlinale, is a striking, experimental debut film from R. Gowtham
3 mins
February 26, 2026
Mint Chennai
AUROBINDO PHARMA TAKES A PENICILLIN SHOT
The company has made a ₹2,500 crore bet to rebuild its antibiotic backbone. Will it work?
6 mins
February 26, 2026
Mint Chennai
Digital rupee pilot for food subsidy
In a significant shift in the way food subsidies are delivered, the government will launch a central bank digital currency (CBDC)-based pilot under the Pradhan Mantri Garib Kalyan Anna Yojana (PMGKAY) in Puducherry on 26 February.
1 min
February 26, 2026
Mint Chennai
DRL's obesity jab may launch in March
Dr. Reddy's Laboratories (DRL) is likely to launch its generic semaglutide injection in the country in March under the brand name Obeda, according to two people familiar with the matter as well as images reviewed by Reuters.
1 min
February 26, 2026
Mint Chennai
Uranium supply deal likely during Carney’s India visit
Cameco CEO Tim Gitzel to be part of the business delegation accompanying Canadian PM
2 mins
February 26, 2026
Mint Chennai
Warner interested in Paramount offer
Warner Bros Discovery Inc. said a new $31-a-share buyout offer from Paramount Skydance Corp. could lead to a better deal than its existing agreement with Netflix Inc., kicking off another potential round of bidding for the famed Hollywood studio.
1 mins
February 26, 2026
Mint Chennai
Hype and havoc shroud Al's impact on IT firms
Is investor anxiety over the business models of IT service companies being rendered obsolete by AI overblown? The truth lies between an apocalypse and AI-impact denial. Here's why
2 mins
February 26, 2026
Mint Chennai
Zydus plans obesity jab in pens after semaglutide patent ends
Ahmedabad-based drugmaker Zydus Lifesciences plans to launch its semaglutide injection brands upon patent expiry of the drug in India.
1 mins
February 26, 2026
Mint Chennai
CHASING 12% EQUITY RETURNS? LONG-TERM INVESTING ISN'T JUST ABOUT A NUMBER
Most investors enter equity mutual funds expecting an annual average return of about 12%.
3 mins
February 26, 2026
Listen
Translate
Change font size

